NuVasive Inc

NuVasive — Q3 2018 Earnings Presentation

12 slides from NuVasive's earnings presentation, Oct 30, 2018

  1. Slide 1: Q3 2018 Results Supplemental Presentation to Earnings Press Release

    Q3 2018 Results Supplemental Presentation to Earnings Press Release October 30, 2018 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    NuVasive, Inc. (“NuVasive,” “NUVA” or the “Company”) cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove co

  3. Slide 3: Non-GAAP Financial Measures

    Management uses certain non-GAAP financial measures such as non-GAAP earnings per share, non-GAAP net income, non-GAAP operating expenses and non-GAAP operating profit margin, which exclude amortization of intangible assets, business transition costs, purchased in-process research and development, o

  4. Slide 4: Financial Performance

    Q3 2018 Financial Performance GAAP diluted earnings per share of $0.30; Non-GAAP diluted earnings per share of $0.56, an increase of approximately 10% over prior year GAAP operating profit margin of 6.6% and non-GAAP operating profit margin of 15.6% Total revenue increased to $271.3 million, up 9.8%

  5. Slide 5: Revenue Drivers

    Q3 2018 Revenue Drivers U.S. Spinal Hardware Includes all Implants, Fixation and NuVasive Specialized Orthopedics (NSO) $146.1 7.0% Growth in case volume of more than 7%, and contributions from new product introductions, partially offset by approximately (2%) pricing pressure U.S. Surgical Support I

  6. Slide 6: P&L Performance Non-GAAP Measures

    Q3 2018 P&L Performance Non-GAAP Measures Q3 2018 Actuals Key Performance Factors Gross Margin 72.8% 70 bps below prior year primarily driven by the acquisition of SafePassage and investment in core NCS Sales, Marketing & Administration 51.6% 70 bps increase from prior year primarily driven by perfo

  7. Slide 7: U.S. Revenue Trends

    U.S. Revenue Trends U.S. Spinal Hardware Growth U.S. Biologics Growth *Includes U.S. Spinal Hardware and U.S. Surgical Support revenue, normalized for impact of Ellipse Technologies, SafePassage and Biotronic acquisitions **Includes clinical services revenue, normalized for impact of SafePassage and

  8. Slide 8: West Carrollton Productivity

    West Carrollton Productivity ~ Absorption Improvement and SKUs Insourced Improved Profitability Increased Utilization from Insourcing Procurement Productivity Improved Throughput FY’19 FY’18 Incremental Volume Savings on Unit Cost +130-150 bps Economies of Scale Machine & Labor Productivity + Varian

  9. Slide 9: New Innovations and Partnerships

    Q3 2018 New Innovations and Partnerships* *Some products not commercially released; NuVasive may not make these products available for commercial sale Surgical Automation Platform with 2D- and 3D-Navigation MAGEC X Early Onset Scoliosis Treatment Biologics Line Extension: Propel DBM, Amniotic Membra

  10. Slide 10: Updated 2018 Full-Year Non-GAAP Guidance

    Updated 2018 Full-Year Non-GAAP Guidance * Financial performance guidance as of July 31, 2018 ** Updated financial performance guidance as of October 30, 2018 Prior 2018 Guidance* Updated 2018 Guidance** $1.095B - $1.105B $1.105B - $1.110B 72.6% ~72.3% 55.9% 56.8% - 57.3% 16.7% 15.0% - 15.5% $2.37 -

  11. Slide 11: 2018 Full-Year Financial Performance Guidance

    2018 Full-Year Financial Performance Guidance* Financial Measures FY18 Guidance Key Performance Factors Revenue (as reported) $1,105M - $1,110M 7.6% to 8.1% growth Includes SafePassage contribution; ~$2M currency tailwind U.S. Spinal Hardware U.S. Surgical Support International 1) ~4% to ~5% YoY gro

  12. Slide 12: For questions, contact [email protected]

    For questions, contact [email protected].

Nuvasive — Q3 2018 Earnings Presentation on 6ix